Fierce Biotech’s 2025 Fierce 15
Jennifer Doudna on Medical Innovation | The Atlantic Festival 2025
The Billionaires Fueling the Quest for Longer Life
Making Personalized Crispr Cures to Save More Babies
Synthetic proteins are being built with the help of AI models
Dealmakers back AI drug discovery boom
The Hidden Barriers Holding Back Cancer’s Most Promising Treatments
Supercomputer named after Nobel laureate Jennifer Doudna
Baby Is Healed With World’s First Personalized Gene-Editing Treatment
TIME 100 Most Influential People of 2025
The Age of CRISPR
Sam Altman-backed Retro Biosciences to raise $1bn for project to extend human life
Dyno Therapeutics Announces Exercise of Option by Roche for Next-Generation AAV Vector for Neurological Gene Therapy
Using AI to design small molecule drugs is tough. Here are five companies trying to crack the code.
Combining AI and Crispr Will Be Transformational
Ataraxis AI Launches to Transform Precision Medicine Beginning with World’s First AI-native Cancer Diagnostic
Roche Bets Up to $1 Billion to Solve Gene Therapy’s Big Problem
Dyno Therapeutics Forms New Strategic Partnership With Roche To Advance AAV Gene Therapy Vectors For Neurological Diseases
Jennifer Doudna on the Brave New World Being Ushered In by Gene Editing
With AI warning, Nobel winner joins ranks of laureates who’ve cautioned about the risks of their own work
Augmenting Humans: From bionic limbs, to smart skin and robot helpers
BioAge Labs Announces Closing of Initial Public Offering, Full Exercise of Underwriters’ Option to Purchase Additional Shares and Closing of the Concurrent Private Placement
The small-town Nobel Prize winner who wants to cure Alzheimer’s in 10 years
10 Most Innovative People of the Last 10 Years
Fareed Zakaria GPS: The gene editing revolution
The race to build better CRISPR delivery vehicles is heating up
Meet the man who combines science, technology and magic to understand proteins
AI gene editing tools have power to modify human DNA, say researchers
AI & drug discovery: A biotech CEO, a scientist, and a venture capitalist separate hype from reality
How crops are being disaster-proofed
New medicine could prevent disease before it begins — but at a cost
Generative A.I. Arrives in the Gene Editing World of CRISPR
Artificial intelligence is taking over drug development
Sam Altman’s mission to increase human lifespan with a $180 million shipping container experiment at Retro Biosciences
Profluent Secures $35M in Additional Funding and Key Industry Experts to Scale Foundational AI Models for Biomedicine and Tackle First Vertical in Gene Editing
Gene-editing pioneer calls for big investment in Crispr technology
Biotech VCs See Room for More Growth in Obesity Drug Market
Antibiotic Resistance is a Looming Crisis. CRISPR May Hold the Answer
BioAge raises $170M as obesity spotlight shifts to oral options, muscle preservers
BioAge Announces $170 Million Oversubscribed Series D Financing to Accelerate Development of Obesity and Metabolic Disease Therapeutics
